← Back to Clinical Trials
Recruiting NCT06246955

NCT06246955 Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06246955
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Hematopoietic and Lymphoid System Neoplasm
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-01-08
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Behavioral Intervention: Group Therapy SessionSurvey Administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-01-08 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This clinical trial tests how well acceptance and commitment therapy and compassion based virtual group therapy works to improve psychological wellbeing, such as compassion, understanding, and flexibility, in patients with cancer. Receiving a cancer diagnosis, undergoing cancer treatment, and living with cancer- or treatment-related symptoms have often been found to be associated with elevated distress and decreased quality of life for individuals, even when the disease is stable or in remission. Acceptance and Commitment Therapy (ACT) has demonstrated considerable benefits on individuals' quality of life, psychological flexibility, and amelioration of psychological distress following a cancer diagnosis and in the face of uncertainty, loss, and challenges associated with cancer.

Eligibility Criteria

Inclusion Criteria: * Being an adult (18 years or older) * Being a patient of Mayo Clinic Arizona * Having a cancer diagnosis, having treatment planning in progress, undergoing cancer-related treatment, or having completed cancer within the past 2 years (in recent survivorship * Experiencing stress or challenges related to cancer and having treatment goals that align with the purpose of the group * Having self reported proficiency to read/write/speak English * Expressing interest and commitment to attend all six virtual group sessions Exclusion Criteria: * Patients' inability to take part in and benefit from the virtual group therapy based on clinical judgment of the psychosocial oncology team member who completes the psychosocial evaluation, which may include having active suicidal or homicidal intent, experiencing uncontrolled psychotic symptoms, having untreated personality disorder/characteristics that are likely disturbing in a group setting, and/or having moderate to severe cognitive impairments

Contact & Investigator

Central Contact

Clinical Trials Referral Office

✉ mayocliniccancerstudies@mayo.edu

📞 855-776-0015

Principal Investigator

Chun Tao, PhD, LP

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT06246955 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06246955 currently recruiting?

Yes, NCT06246955 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.

Where is the NCT06246955 trial being conducted?

This trial is being conducted at Scottsdale, United States.

Who is sponsoring the NCT06246955 clinical trial?

NCT06246955 is sponsored by Mayo Clinic. The principal investigator is Chun Tao, PhD, LP at Mayo Clinic. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology